Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

Clinical Trial ID NCT04513158

PubWeight™ 0.00‹?›

🔗 Visit the page for NCT04513158

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020 18.57
2 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 18.32
3 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 10.16
4 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020 10.13
5 Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 6.59
6 Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med 2016 6.22
7 The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2014 1.88
8 Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011 1.68
9 Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003 1.40
10 Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005 1.23
11 Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus 2015 0.96
Next 100